Hormone-Refractory Oncology Drug Market Report 2026

The hormone-refractory oncology drug market size has grown rapidly in recent years. It will grow from $3.93 billion in 2025 to $4.4 billion in 2026 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to increasing prevalence of prostate and breast cancer cases globally, growing reliance on hormone therapy in early stage cancer treatment, expansion of oncology drug research and clinical trials, rising adoption of chemotherapy and endocrine therapy combinations, increasing healthcare expenditure on cancer treatment and hospital oncology infrastructure.

The hormone-refractory oncology drug market size is expected to see rapid growth in the next few years. It will grow to $6.95 billion by 2030 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to growth in precision medicine and biomarker based oncology treatments, increasing development of next generation targeted cancer therapies, rising adoption of combination immunotherapy and small molecule drugs, expansion of personalized oncology treatment pathways in hospitals, increasing regulatory approvals for advanced refractory cancer drugs. Major trends in the forecast period include increasing adoption of targeted kinase inhibitors and next generation biologics for resistant cancer types, rising use of combination therapy approaches to overcome hormone resistance in oncology treatment, expansion of precision oncology enabling biomarker driven treatment selection for advanced cancers, growing development of immunotherapy based alternatives for hormone refractory cancer management, increasing shift toward oral oncology drugs for improved patient compliance in long term treatment.

The increasing prevalence of hormone-resistant cancers is expected to propel the growth of the hormone-refractory oncology drug market going forward. Hormone-Resistant Cancers are cancers that continue to grow or spread despite treatment with hormone-blocking therapies, such as castration-resistant prostate cancer (CRPC) or endocrine-resistant breast cancer. The rising prevalence of hormone-resistant cancers is driven by prolonged exposure to endocrine (hormone) therapies, which is contributing to tumor cells adapting and developing resistance mechanisms over time. Hormone-refractory oncology drug development supports and propels the management of these resistant disease states by providing targeted therapeutic options when conventional hormone therapies fail, thereby strengthening treatment outcomes. For instance, in October 2025, according to NHS England, a UK-based publicly funded healthcare system, there were 354,820 new cancer diagnoses in 2023, which is 8,605 more than in 2022. Therefore, the increasing prevalence of hormone-resistant cancers is driving the growth of the hormone-refractory oncology drug market.

Leading companies operating in the hormone-refractory oncology drug market are focusing on biomarker-driven targeted therapies that inhibit specific molecular pathways responsible for resistance to hormone therapy. Biomarker-driven targeted therapies refer to treatments designed to identify genetic alterations and selectively block signaling pathways that enable tumor growth after endocrine therapy failure. For example, in November 2023, AstraZeneca, a UK-based pharmaceutical company, received U. S. Food and Drug Administration (FDA) approval for Truqap (capivasertib) for use in combination with fulvestrant for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer with PIK3CA, AKT1, or PTEN alterations following disease progression. This therapy selectively inhibits the AKT signaling pathway and incorporates biomarker-based patient selection to improve treatment outcomes. The approval was supported by positive Phase III CAPItello-291 trial results demonstrating improved progression-free survival in patients with these genetic alterations, strengthening AstraZeneca’s oncology portfolio and expanding treatment options for patients with hormone-resistant breast cancer.

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for $43 billion. Through this acquisition, Pfizer strengthened its oncology portfolio by integrating advanced antibody-drug conjugate (ADC) technologies, expanded its precision oncology capabilities to address treatment-resistant cancers, and enhanced its global market reach through a broader and more differentiated pipeline. Seagen Inc. is a US-based biotechnology company developing targeted cancer therapies, with a core focus on antibody-drug conjugates designed to selectively deliver cytotoxic agents to tumor cells.

Major companies operating in the hormone-refractory oncology drug market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi S. A., Novartis AG, AstraZeneca plc, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Incyte Corporation, Ipsen S. A., Exelixis Inc., Arvinas Inc., Nuvation Bio Inc., Immunic Inc., Noxopharm Limited, Accutar Biotechnology Inc.

North America was the largest region in the hormone-refractory oncology drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hormone-refractory oncology drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hormone-refractory oncology drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hormone-refractory oncology drugs market consists of sales of abiraterone acetate tablets, enzalutamide capsules, docetaxel injection, cabazitaxel injection, mitoxantrone injection, prednisone tablets, hydrocortisone tablets, and zoledronic acid injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.